Stellar Biotech Limited
Stellar Biotech Limited
With innovation as the engine and resources as the lever,
empowering the global value chain of the pharmaceutical industry
With innovation as the engine and resources as the lever,
empowering the global value chain of the pharmaceutical industry
WHO WE ARE
Stellar Biotech Limited
Stellar Biotech Limited
Stellar Biotech is a global life health company with its headquarters located in both Singapore and Hong Kong. It possesses professional capabilities in the cross-regional introduction, research and development, production, and commercialization of pharmaceuticals and medical devices. There are 4 subsidiaries, mainly focusing on innovative drugs, generic drugs, traditional Chinese medicines, and medical devices. They cover the demands of different treatment fields and are dedicated to the global life health sector. They accelerate the transformation and popularization of medical innovation achievements, injecting strong impetus into the development of human health.
Stellar Biotech is a global life health company with its headquarters located in both Singapore and Hong Kong. It possesses professional capabilities in the cross-regional introduction, research and development, production, and commercialization of pharmaceuticals and medical devices. There are 4 subsidiaries, mainly focusing on innovative drugs, generic drugs, traditional Chinese medicines, and medical devices. They cover the demands of different treatment fields and are dedicated to the global life health sector. They accelerate the transformation and popularization of medical innovation achievements, injecting strong impetus into the development of human health.
One-Stop End-to-End Service Capabilities
One-Stop End-to-End Service Capabilities
Customized Order Cooperation Case
Customized Order Cooperation Case
About Us
About Us
The core team members all have over 15-20 years of industry experience, and have a deep understanding of the markets in Southeast Asia and Hong Kong. They provide clients with professional, efficient and compliant global solutions.
Mr. Lin Mengxuan
Mr. Lin Mengxuan
An experienced leader in the medical and health industry, with over 15 years of experience in strategic planning, business management, and global diversified market capital operation.
Mr. Liu Weimin
Mr. Liu Weimin
With rich experience in pharmaceutical distribution and a strategic vision, he/she has been responsible for establishing a large and efficient logistics system, and successfully implemented multiple national-level public health service projects.
Dr. Wu Zhihao
Dr. Wu Zhihao
An experienced scientist with over 20 years of professional experience in antibody engineering and tumor immunology, has led the development of therapeutic antibodies at top institutions.
Dr. Maple Wu
Dr. Maple Wu
Specialized in registration science, gene and cell therapy, as well as the research and development of oncology drugs. Has held important positions at the Singapore Health Sciences Authority (HSA) for a long time. Member of the International Pharmaceutical Registration Professionals Association (IPRP).
Dr. Aiden Lee
Dr. Aiden Lee
An experienced medical affairs expert with a diverse background covering multiple treatment areas such as diabetes, immunology, and oncology.
Mrs.Sabrina Chew
Mrs.Sabrina Chew
Having over 20 years of marketing and sales experience in the pharmaceutical and healthcare fields, he has held several leadership positions at Bayer Company.
Brand Influence & Global Expansion
Brand Influence & Global Expansion
November 2025
December 19th, 2025
The Leading Board of Singapore has been released
Stellar Biotech has enabled "Chinese medicine" to reach the world
The Leading Board of Singapore has been released
Stellar Biotech has enabled "Chinese medicine" to reach the world
2025 T-EDGE Global Summit
Stellar Biotech Demonstrates the Strong Core Competence of Chinese Innovative Drugs Going Global
2025 T-EDGE Global Summit
Stellar Biotech Demonstrates the Strong Core Competence of Chinese Innovative Drugs Going Global
Case Benchmark
Case Benchmark
Pharmaceutical's Overseas Expansion Strategy Plan
Pharmaceutical's Overseas Expansion Strategy Plan
Precise procurement of kidney dialysis supplies
Precise procurement of kidney dialysis supplies
Platelet Growth Factor Project
Platelet Growth Factor Project
Pharmaceutical project in QM granules
Pharmaceutical project in QM granules
Positioning: The Breakthrough Player in China's Emerging Biopharmaceutical Market
Positioning: The Breakthrough Player in China's Emerging Biopharmaceutical Market
Product features: Leading-edge innovative drugs globally, occupying an absolute leading position in the treatment market for thrombocytopenia in China.
Product features: Leading-edge innovative drugs globally, occupying an absolute leading position in the treatment market for thrombocytopenia in China.
Time and Place: August 25-26, 2025, Shanghai
Time and Place: August 25-26, 2025, Shanghai
Product features: Chinese patent medicine powder, effectively alleviates diabetic macular edema.
Product features: Chinese patent medicine powder, effectively alleviates diabetic macular edema.
Core objective: By 2028, overseas revenue will account for 35% (in 2024: 12%), and the market share in Southeast Asia will enter the top 3.
Core objective: By 2028, overseas revenue will account for 35% (in 2024: 12%), and the market share in Southeast Asia will enter the top 3.
Product strategy: Focus on high-barrier market segments, with differentiated selling points and design of access pathways
Product strategy: Focus on high-barrier market segments, with differentiated selling points and design of access pathways
Regional layout: Malaysian production line + Singapore - Jakarta dual logistics center
Regional layout: Malaysian production line + Singapore - Jakarta dual logistics center
Sea exploration challenge: Lack of overseas commercialization experience, with only approval in 10 smaller countries.
Sea exploration challenge: Lack of overseas commercialization experience, with only approval in 10 smaller countries.
Stellar Solution:
HSA + NPRA simultaneous registration
NPP's rapid implementation
Expected sales volume of 600 million yuan in 5 years.
Has entered National University Hospital of Singapore, Curie Cancer Hospital, etc.
Stellar Solution:
HSA + NPRA simultaneous registration
NPP's rapid implementation
Expected sales volume of 600 million yuan in 5 years.
Has entered National University Hospital of Singapore, Curie Cancer Hospital, etc.
Partner: Stellar Biotech + China Logistics and Purchasing Federation Medical Devices Branch
Partner: Stellar Biotech + China Logistics and Purchasing Federation Medical Devices Branch
Purchase volume: Over 15 SKUs, approximately 200 million yuan
Purchase volume: Over 15 SKUs, approximately 200 million yuan
Service model: Targeted invitation - Precise promotion - On-site signing, one-stop service
Service model: Targeted invitation - Precise promotion - On-site signing, one-stop service
Market value: Fill the gap in market drug treatment, traditional Chinese medicine in Southeast Asia has high acceptance rate and the market is vast.
Market value: Fill the gap in market drug treatment, traditional Chinese medicine in Southeast Asia has high acceptance rate and the market is vast.
Project outcome: Rapid registration of traditional Chinese medicine, entering the market within 6 months, and achieving commercial authorization.
Project outcome: Rapid registration of traditional Chinese medicine, entering the market within 6 months, and achieving commercial authorization.
Strategic Partners
Strategic Partners
艾社康
艾社康
艾社康 With profound influence in healthcare policies and rich resources in the high-end industrial ecosystem in the Asia-Pacific region, we focus on innovative therapies for nephrology and dialysis consumables, jointly building a platform for cross-border technology exchange and business connection.
Help build an international exchange platform, jointly explore the offshore cooperation models of Macao, Hong Kong and other places, and promote the cross-border business layout.
艾媒咨询
艾媒咨询
The world's leading third-party data mining and analysis institution in the new economy industry has collaborated with Stellar Biotech to release the "AiiMedia Golden List - 2025 China Innovative Drug Overseas Expansion Leadership List", establishing an authoritative benchmark system for the industry.
In November 2025, Singapore released the country's first professional list for the overseas promotion of innovative drugs.
三生制药
三生制药
Representatives of China's leading biopharmaceutical companies gathered together with Stellar Biotech for the 2025 T-EDGE Global Dialogue, jointly exploring the strategies and practices for Chinese innovative drugs to go global.
Industry leaders gathered to discuss together, jointly promoting the globalization process of innovative drugs in China.
中国物流与采购联合会
中国物流与采购联合会
The Medical Devices Branch has carried out strategic cooperation, leveraging its industry resources to precisely connect with domestic high-quality medical device enterprises. They jointly held a closed-door meeting on renal dialysis consumables in Singapore, achieving efficient connections.
Targeted invitation of enterprises + Precise product promotion + On-site signing of cooperation agreements
Highlights of Cooperation
Highlights of Cooperation
Cooperative Value
Cooperative Value
Cooperative achievements
Cooperative achievements
Cooperative model
Cooperative model